Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors
Robin E. Norris(Rainbow Babies & Children's Hospital), Rochelle Bagatell(Children's Hospital of Philadelphia), Lia Gore(Children's Hospital Colorado), Elizabeth Fox(Children's National), Margaret E. Macy(Children's Hospital Colorado), Suzanne Shusterman(Dana-Farber Cancer Institute), Jodi A. Muscal(Baylor College of Medicine), Noah Berkowitz(Arvinas (United States)), Aby Buchbinder(Enzon Pharmaceuticals (United States))
Cited by 34
Related Papers
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341